Search Results
Your search for 3 matches 15623 pages
Showing 7551 - 7600Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma
Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...
Role of IL-6/JAK1 Pathway in the Treatment of Hepatocellular Carcinoma
A recent study published by Chan et al in the Journal of Clinical Investigation found a cellular pathway associated with cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma. IL-6/JAK1 Pathway Researchers...
Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends
A new study finds that trends in colonoscopy rates did not fully align with recent increases in colorectal cancer incidence in younger adults. The findings were published by Fedewa et al in the Journal of Medical Screening. Colorectal cancer incidence rates are declining in adults older than...
Incidence of Olaratumab Infusion-Related Reactions
In a study reported in the Journal of Oncology Practice, Van Tine et al found that infusion-related reactions occurred in 14.4% of patients receiving olaratumab in clinical trials, with grade ≥ 3 events occurring in 2.3%. (Olaratumab was withdrawn from the global market on April 25, 2019, based...
Role of Regulatory T Cells in Predicting Breast Cancer Relapse
Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...
Neoadjuvant Radiotherapy vs Surgery Alone for Resectable Hepatocellular Carcinoma With Tumor Thrombus
In a Chinese study reported in the Journal of Clinical Oncology, Wei et al found that neoadjuvant three-dimensional conformal radiotherapy improved outcomes vs hepatectomy alone in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus. Study Details In the multicenter...
Addition of Preoperative NBTXR3 to Radiotherapy in Locally Advanced Soft-Tissue Sarcoma
In the phase II/III Act.In.Sarc trial reported in The Lancet Oncology, Bonvalot et al found that preoperative addition of the radioenhancer hafnium oxide nanoparticle NBTXR3 to radiotherapy may improve outcomes in patients with locally advanced soft-tissue sarcoma. The agent acts to increase...
Ivosidenib for Advanced IDH1-Mutated Advanced Cholangiocarcinoma
Ivosidenib, a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), is currently being studied in a phase I clinical trial assessing its efficacy in patients with IDH1-mutated solid tumors. In a report published by Lowery et al in The Lancet Gastroenterology & Hepatology, researchers...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia
In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia. The trial,...
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events
In a study reported in JAMA Oncology, Simonaggio et al found that rechallenge with an immune checkpoint inhibitor after occurrence of immune-related adverse events was associated with occurrence of an immune-related adverse event in approximately half of patients, with no increase in severity....
ReDOS: Regorafenib Dose-Escalation Strategy in Refractory Advanced Colorectal Cancer
In the phase II ReDOS trial reported in The Lancet Oncology, Bekaii-Saab et al found that a regorafenib dose-escalation strategy compared favorably with standard dosing in regard to toxicity profile and activity in patients with refractory advanced colorectal cancer. Study...
Combination Therapy With Immunochemotherapy and an Antibody-Drug Conjugate in DLBCL
As reported in The Lancet Oncology, Hervé Tilly, MD, and colleagues found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in ...
Effect of Bortezomib/Dexamethasone Plus Pomalidomide on Progression-Free Survival in Multiple Myeloma Pretreated With Lenalidomide
In the phase III OPTIMISMM trial, reported by Paul G. Richardson, MD, and colleagues in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with...
Addition of Antiangiogenic Agent to First-Line Carboplatin/Paclitaxel in Ovarian Cancer
In a phase III trial (TRINOVA-3/ENGOT-ov2/GOG- 3001) reported in The Lancet Oncology, Ignace Vergote, PhD, and colleagues found that addition of the antiangiogenic agent trebananib to carboplatin/ paclitaxel did not improve progression-free survival in first-line treatment of advanced ovarian...
Henry T. Lynch, MD, Trailblazer in Hereditary Cancers, Dies at 91
Henry T. Lynch, MD, widely known as “the father of cancer genetics,” had an early life that could have been lifted from the pages of a Louis L’Amour novel. He dropped out of high school and using a falsified birth certificate joined the U.S. Navy at 16 years old, serving as a gunner on a marine...
Chaga Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, explore the current...
How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy
Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...
FDA Approves New Trastuzumab Biosimilar
On June 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 22, trifluridine/tipiracil...
Benefit Seen With Targeted Therapies in Elderly and Medically Complex Patients With Metastatic RCC
Many elderly and medically complex patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials—saw overall survival benefits from treatment with targeted therapies, according to a study that analyzed 13 years of data on Medicare patients...
Anti-KIR3DL2 Monoclonal Antibody for Relapsed or Refractory Cutaneous T-Cell Lymphoma
In a phase I trial reported in The Lancet Oncology, Bagot et al found that IPH4102—a first-in-class monoclonal antibody targeting KIR3DL2—was safe and showed activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome....
ESMO World GI 2019: BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the phase III BEACON CRC clinical trial. These findings were presented by Kopetz et al at the European...
ESMO World GI 2019: REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer
Regorafenib is often administered to patients with refractory metastatic colorectal cancer. However, some of the adverse events related to the use of this drug often limit its use in clinical practice. A study reported by Argilés et al at the European Society for Medical Oncology (ESMO)...
FDA Grants Accelerated Approval to Selinexor in Combination With Dexamethasone in Pentarefractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two...
Combination Immunotherapy and Inhibitors of DNA Damage Repair in the Treatment of Small Cell Lung Cancer
Unlike non–small cell lung cancer (NSCLC), which has seen a paradigm shift in treatment modalities with the discovery of genetic signatures (including EGFR mutations) that are responsive to targeted drugs, systemic treatment of small cell lung cancer (SCLC) has remained largely unchanged for over...
APACT Trial: Nab-paclitaxel/Gemcitabine vs Gemcitabine Alone in Adjuvant Treatment of Pancreatic Cancer
The largest adjuvant trial in pancreatic adenocarcinoma, the global phase III APACT trial, evaluated the combination of adjuvant nab-paclitaxel/gemcitabine vs gemcitabine monotherapy in patients with resected pancreatic cancer. Results of the study were reported by Margaret A. Tempero, MD, of the...
SOPHIA Trial Tests Margetuximab in Heavily Pretreated Patients With HER2-Positive Metastatic Breast Cancer
In the phase III SOPHIA trial of 536 heavily pretreated patients with HER2-positive metastatic breast cancer, the novel anti-HER2 antibody margetuximab plus chemotherapy led to significant improvements in progression-free survival, response, and clinical benefit compared with...
Enfortumab Vedotin After Checkpoint Inhibition in Metastatic Urothelial Cancer
A phase II study found that treatment with the antibody-drug conjugate enfortumab vedotin achieved responses in 44% of patients with locally advanced or metastatic urothelial cancer previously treated with platinum chemotherapy and a checkpoint inhibitor. This is a noteworthy study because it...
Study Shows Benefit With Pazopanib in Treatment of Carcinoid Tumors
Pazopanib significantly improved progression-free survival by 47% in patients with progressive carcinoid tumors, in a prospective randomized phase II trial presented at the 2019 ASCO Annual Meeting.1 “With these results, Alliance A021202 becomes the first randomized study to show that the vascular...
Expert Point of View: Jordan Berlin, MD
Jordan Berlin, MD, the Ingram Professor of Cancer Research and Professor of Medicine at Vanderbilt University Medical Center, Nashville, discussed the FOxTROT study at the oral session. “FOxTROT did reach its targeted hazard ratio, but the bottom line is the P value did not quite make it to where...
Expert Point of View: Hanna K. Sanoff, MD, MPH
Study discussant Hanna K. Sanoff, MD, MPH, of the University of North Carolina Lineberger Comprehensive Center, summarized the key results of VISNU-1: first, survival is shorter for patients with high circulating tumor cell (CTC) count; second, the incremental benefit from FOLFOXIRI (fluorouracil...
Targeting FOLFOXIRI Plus Bevacizumab to a Metastatic Colorectal Cancer Subset
In a population of patients with metastatic colorectal cancer deemed to be at high risk by the presence of circulating tumor cells (CTCs), first-line treatment with FOLFOXIRI plus bevacizumab improved progression-free survival by about 3 months, compared with modified FOLFOX plus bevacizumab,...
Expert Point of View: David P. Ryan, MD
The primary analysis of the IDEA trial demonstrated that low-risk stage III colorectal cancer could be acceptably treated with 3 months of capecitabine plus oxaliplatin (CAPOX), invited discussant David P. Ryan, MD, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center,...
IDEA Collaboration Turns to Duration of Adjuvant Treatment in Stage II Colon Cancer
The findings of the landmark IDEA trial in stage III colorectal cancer, presented at the 2017 ASCO Annual Meeting and subsequently published in The New England Journal of Medicine,1 were upheld by a subsequent analysis by the same group, the International Duration Evaluation of Adjuvant...
Activity of Niraparib Plus Pembrolizumab in Recurrent Ovarian Carcinoma
In a pooled analysis of the phase I/II TOPACIO/KEYNOTE-162 study reported in JAMA Oncology, Konstantinopoulos et al found evidence of activity of combined niraparib and pembrolizumab in a cohort of patients with recurrent ovarian carcinoma. Study Details The analysis included 60 evaluable women...
Advances in Targeted Therapy for Non–Small Cell Lung Cancer
Targeted therapies for non–small cell lung cancer (NSCLC) are a hotbed of investigation. Two new targeted therapies are promising for patients with lung tumors that are either EGFR exon 20 insertions or RET-rearranged. At the 2019 ASCO Annual Meeting, attendees heard early data on therapies...
Pexidartinib for Advanced Tenosynovial Giant Cell Tumors
In the phase III ENLIVEN trial reported in The Lancet, Tap et al found that the colony-stimulating factor 1 inhibitor pexidartinib produced responses in patients with advanced tenosynovial giant cell tumors (TGCTs) not amenable to surgical resection. Study Details In the double-blind portion of...
Neoadjuvant Immunotherapy May Benefit Patients With Early-Stage NSCLC
Neoadjuvant immunotherapy had encouraging activity and demonstrated favorable safety in patients with resectable early-stage non–small cell lung cancer (NSCLC), according to two studies presented at the 2019 ASCO Annual Meeting.1,2 This approach has the potential to boost the survival rate in...
NALA Trial: Neratinib Plus Capecitabine Shows Benefit in Metastatic Breast Cancer
In the global phase III NALA trial, treatment of metastatic HER2-positive breast cancer with neratinib plus capecitabine significantly improved progression-free survival, delayed the time to intervention for central nervous system disease, and showed a trend toward improved overall survival vs...
Clinical Risk Enhances Utility of TAILORx Findings in Young Women With Breast Cancer
Clinical risk factors add prognostic information that complements the 21-gene recurrence score, according to a new analysis from the landmark TAILORx trial.1,2 The integration of clinical risk with the recurrence score provides greater precision in determining recurrence risk and guiding the use of ...
Winning the Lottery
I was born at the beginning of World War II in a country half way around the world from the fighting. As a child, I was immune to the carnage. My father was too old to be included, although his elder brother had been killed in World War I. Thousands of families in many countries lost a father, a...
Treatment of Immune Checkpoint Inhibitor Immune-Related Cutaneous Adverse Events
In a study reported in the Journal of Clinical Oncology, Phillips et al found that immune-related cutaneous adverse events in patients receiving immune checkpoint inhibitors generally responded to symptom- and phenotype-directed dermatologic therapies, and that biologic therapies were effective in...
ECHO-301/KEYNOTE-252: Addition of Epacadostat to Pembrolizumab in Unresectable or Metastatic Melanoma
As reported in The Lancet Oncology by Long et al, the phase III ECHO-301/KEYNOTE-252 trial showed no improvement in progression-free or overall survival with the addition of the IDO1 inhibitor epacadostat to pembrolizumab in unresectable stage III or stage IV melanoma. Study Details In the...
Extended Follow-up From the National Lung Screening Trial Reported
Early detection and treatment through screening with low-dose computed tomography (LDCT) has been investigated as a potential means of reducing lung cancer mortality for more than 2 decades. In 2011, a large U.S. study—the randomized National Lung Screening Trial (NLST)—reported a 20%...
SNMMI 2019: Peptide Receptor Radionuclide Therapy May Be Effective in High-Grade Neuroendocrine Neoplasms
Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 neuroendocrine neoplasms, according to research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and published by Zhang et al in The...
Evaluation of PROMIS Measures After Radical Prostatectomy
In a study reported in the Journal of Clinical Oncology, Agochukwu et al validated the sexual interest and sexual satisfaction single-item measures of the Patient-Reported Outcome Measurement Information System (PROMIS) in men who underwent radical prostatectomy for prostate cancer. The study ...
15-ICML: Adding Lenalidomide to R-CHOP in Newly Diagnosed DLBCL
In the phase II ECOG-ACRIN 1412 trial, presented by Nowakowski et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 006), researchers sought to compare the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) vs...
Failure-Free Survival With Ultrahypofractionated vs Conventionally Fractionated Radiotherapy in Prostate Cancer
In the Scandinavian phase III HYPO-RT-PC trial reported in The Lancet, Widmark et al found that ultrahypofractionated radiotherapy was noninferior to conventionally fractionated radiotherapy in failure-free survival in patients with intermediate- to high- risk prostate cancer. Study Details In...
FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval ...
